Lu Chunhua

Lu Chunhua is the Executive Director of Corporate Communication at Innovent Biologics, a leading biopharmaceutical company in China. Recently in the news for the successful inclusion of a novel oral BCL-2 inhibitor for treating B-cell malignant lymphoma in the 'List of New Technologies and Products' at the 2025 Zhongguancun Forum, Lu emphasized the importance of policy reforms in accelerating drug development timelines.